# Aravax Reports Positive Phase 2 Results for Peanut Allergy Therapy PVX108 in Young Children

> Aravax's PVX108 met its Phase 2 primary endpoint in children aged 4-11, with the 50nmol dose lifting tolerated peanut 2.4-fold versus 1.2-fold on placebo.

- Published: 2026-11-12T22:55:02+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-12/aravax-pvx108-phase-2-peanut-allergy
- Source: [Mirage News](https://www.miragenews.com/aravax-reports-positive-phase-2-results-for-1776743/)

## Key takeaways

- Aravax's Phase 2 trial of PVX108 met its primary efficacy endpoint, with the 50nmol dose producing a 2.4-fold increase in maximum tolerated peanut dose versus 1.2-fold for placebo.
- At month 12, 39.4% of children on PVX108 50nmol tolerated at least 443mg of peanut protein, compared with 16.7% on placebo.
- Full topline results are scheduled for presentation by Brian P. Vickery at the ACAAI meeting in Phoenix on November 14, 2026.

Aravax reported positive topline Phase 2 results for PVX108, its peanut allergy immunotherapy, in children aged 4 to 11, with the 50nmol dose producing a 2.4-fold increase in maximum tolerated peanut dose from baseline to month 12 against 1.2-fold for placebo. [Mirage News](https://www.miragenews.com/aravax-reports-positive-phase-2-results-for-1776743/) published the company's announcement on November 12, 2026.

## How the PVX108 Phase 2 Trial Was Run

[Aravax](https://akta.pro/company-profiles/0000nl3/aravax) is a clinical-stage biotechnology company developing peptide-based immunotherapies for food allergy. PVX108 is an investigational therapy that uses proprietary peptides intended to retrain the immune system to tolerate peanut while limiting treatment-induced acute allergic reactions, and it holds FDA Fast Track designation for peanut allergy.

The trial (AVX-201: NCT05621317) ran across 14 sites in the US and Australia. A pilot safety cohort enrolled 24 adolescents aged 12 to 17, and a primary efficacy and safety cohort enrolled 71 children aged 4 to 11. The randomized, double-blind, placebo-controlled treatment period tested monthly intradermal PVX108 at 5 nmol and 50 nmol against placebo over 12 months, with efficacy measured by a double-blind placebo-controlled food challenge following PRACTALL guidelines.

In the 50nmol group (n=23) versus placebo (n=24), 39.4% of participants tolerated a cumulative dose of at least 443mg of peanut protein at month 12, compared with 16.7% on placebo. More than two thirds of adverse reactions to the baseline reactive dose were graded zero or mild in the PVX108 group, against 35% in the placebo group. No treatment-related allergic adverse events, including anaphylaxis, or treatment-related serious adverse events were reported for either dose.

"PVX108 is the first therapy designed to precisely target the root cause of peanut allergy," said Dr Pascal Hickey, CEO of Aravax. "This study shows that PVX108 could meaningfully impact peanut allergy in young children."

## Aravax's Funding and Board Additions

Aravax's Series B round closed in January 2024 at US$42.2 million, according to akta.pro [company records](https://akta.pro/company-data), with investments from Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper and Agati Capital. The same records list an initial tranche of US$20 million announced in December 2022 from Brandon Capital and Tenmile, and total funding of $42.2 million.

The records also show board appointments in April 2026 of Carsten Hellmann, former CEO of ALK-Abello, and Andrew Oxtoby, former chief commercial officer of Aimmune Therapeutics, to support Phase 3 preparation and commercial readiness.

## When the PVX108 Data Will Be Presented

Brian P. Vickery, MD, Chief of Allergy and Immunology at Children's Healthcare of Atlanta, will present the full topline results at 16:30 MST on November 14, 2026, in a late-breaking oral abstracts session at the ACAAI Annual Scientific Meeting in Phoenix, Arizona. Associate Professor Edwin Kim of the University of North Carolina will present the data in an oral session at the FAAM-EUROBAT-ISMA meeting in Utrecht, Netherlands, on November 20, 2026. Aravax said 59 of the 68 completers, or 87%, elected to continue in a 12-month open-label extension study, with results anticipated in the second half of 2027.

## Companies in this story

- [Aravax company profile](https://akta.pro/company-profiles/0000nl3/aravax) · website: http://www.aravax.com.au

---
News for Agent · https://newsforagent.com/llms.txt